Cargando…

Comparison of FDA Approved Kinase Targets to Clinical Trial Ones: Insights from Their System Profiles and Drug-Target Interaction Networks

Kinase is one of the most productive classes of established targets, but the majority of approved drugs against kinase were developed only for cancer. Intensive efforts were therefore exerted for releasing its therapeutic potential by discovering new therapeutic area. Kinases in clinical trial could...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Jingyu, Wang, Panpan, Yang, Hong, Zhou, Jin, Li, Yinghong, Li, Xiaoxu, Xue, Weiwei, Yu, Chunyan, Tian, Yubin, Zhu, Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980536/ https://www.ncbi.nlm.nih.gov/pubmed/27547755 http://dx.doi.org/10.1155/2016/2509385

Ejemplares similares

FDA-approved immunosuppressants targeting staphylococcal superantigens: mechanisms and insights
por: Krakauer, Teresa
Publicado: (2017)

Anti-Cancer Drugs Targeting Protein Kinases Approved by FDA in 2020
por: Cicenas, Jonas, et al.
Publicado: (2021)

Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma
por: Cho, Su Min, et al.
Publicado: (2022)

Quantitative analysis on the characteristics of targets with FDA approved drugs
por: Sakharkar, Meena K., et al.
Publicado: (2007)

Novel targeted drugs approved by the NMPA and FDA in 2019
por: Wang, Wenjing, et al.
Publicado: (2020)

Identification of FDA-approved drugs targeting the Farnesoid X Receptor
por: van de Wiel, Sandra M. W., et al.
Publicado: (2019)

Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells
por: Hou, Zhi-Jie, et al.
Publicado: (2015)

Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials
por: Nishikawa, Shigeto, et al.
Publicado: (2023)

Pantoprazole, an FDA-approved proton-pump inhibitor, suppresses colorectal cancer growth by targeting T-cell-originated protein kinase
por: Zeng, Xiaoyu, et al.
Publicado: (2016)

An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy
por: Tong, Juliana T. W., et al.
Publicado: (2021)

FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023)

Targeted Therapy for Cancers: From Ongoing Clinical Trials to FDA-Approved Drugs
por: Choi, Ha Yeong, et al.
Publicado: (2023)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders
por: Lui, Austin, et al.
Publicado: (2022)

Molecular Recognition of FDA-Approved Small Molecule Protein Kinase Drugs in Protein Kinases
por: Zhu, Yan, et al.
Publicado: (2022)

A Repurposing Approach for Uncovering the Anti-Tubercular Activity of FDA-Approved Drugs with Potential Multi-Targeting Profiles
por: Battah, Basem, et al.
Publicado: (2019)

The Human Kinome Targeted by FDA Approved Multi-Target Drugs and Combination Products: A Comparative Study from the Drug-Target Interaction Network Perspective
por: Li, Ying Hong, et al.
Publicado: (2016)

Overview of the Side-Effects of FDA- and/or EMA-Approved Targeted Therapies for the Treatment of Hematological Malignancies
por: Constantinescu, Catalin, et al.
Publicado: (2020)

Why Did the FDA Approve These Advertisements?
por: Oaks, David
Publicado: (2006)

FDA approved ready to use phenylephrine
por: Bhatia, Pradeep Kumar, et al.
Publicado: (2021)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

FDA-approved medications that impair human spermatogenesis
por: Ding, Jiayi, et al.
Publicado: (2016)

FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy
por: Bhatnagar, Vishal, et al.
Publicado: (2017)

Activity Profile of an FDA-Approved Compound Library against Schistosoma mansoni
por: Panic, Gordana, et al.
Publicado: (2015)

Identification of FDA-approved Drugs Targeting Breast Cancer Stem Cells Along With Biomarkers of Sensitivity
por: Bhat-Nakshatri, Poornima, et al.
Publicado: (2013)

Virtual screening FDA approved drugs against multiple targets of SARS‐CoV‐2
por: Liang, Hualou, et al.
Publicado: (2021)

Geroscience‐guided repurposing of FDA‐approved drugs to target aging: A proposed process and prioritization
por: Kulkarni, Ameya S., et al.
Publicado: (2022)

Identification of natural products and FDA-approved drugs for targeting cancer stem cell (CSC) propagation
por: Bonuccelli, Gloria, et al.
Publicado: (2022)

Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases
por: Mayence, Annie, et al.
Publicado: (2019)

FDA approved drugs as potential Ebola treatments
por: Ekins, Sean, et al.
Publicado: (2015)

FDA approved antibacterial drugs: 2018-2019
por: Andrei, Stefan, et al.
Publicado: (2019)

The current landscape of the FDA approved companion diagnostics
por: Jørgensen, Jan Trøst
Publicado: (2021)

FDA-Approved Oximes and Their Significance in Medicinal Chemistry
por: Dhuguru, Jyothi, et al.
Publicado: (2022)

FDA approved vaccines for monkeypox: Current eminence
por: Chopra, Hitesh, et al.
Publicado: (2022)

Novel use of FDA-approved drugs identified by cluster analysis of behavioral profiles
por: Tucker Edmister, Sara, et al.
Publicado: (2022)

Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection
por: Tshiani Mbaya, Olivier, et al.
Publicado: (2021)

Olumniant (Baricitinib) oral tablets: An insight into FDA-approved systemic treatment for Alopecia Areata
por: Ali, Eman, et al.
Publicado: (2022)

Molecular Markers for Bladder Cancer Screening: An Insight into Bladder Cancer and FDA-Approved Biomarkers
por: Flores Monar, Gabriela Vanessa, et al.
Publicado: (2023)

Exploring the Inhibitory Mechanism of Approved Selective Norepinephrine Reuptake Inhibitors and Reboxetine Enantiomers by Molecular Dynamics Study
por: Zheng, Guoxun, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_u6ju26lepjkmp7mfsgoviddolp